Market Cap 73.35M
Revenue (ttm) 0.00
Net Income (ttm) -79.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 103,200
Avg Vol 895,636
Day's Range N/A - N/A
Shares Out 33.19M
Stochastic %K 64%
Beta 0.91
Analysts Hold
Price Target $1.00

Company Profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessiv...

Industry: Biotechnology
Sector: Healthcare
Phone: 786 629 1376
Address:
2222 Ponce de Leon Blvd., Floor 3, Coral Gables, United States
signaljumper
signaljumper Oct. 20 at 4:43 PM
$RLMD loading at this area
0 · Reply
VictorMason
VictorMason Oct. 20 at 4:05 PM
$RLMD Jan 23rd text to grandson: Im buying 20,000 RLMD at .36 $7200 in anticipation of something happening w the dissolution of assets planned. The Net Operating Loss of $640MM is worth at least $3/ share to a profitable pharma, the Relight phase 3 and develop the P-12 are valuable as is the $1 per share in cash
2 · Reply
RebelWithoutAPause777
RebelWithoutAPause777 Oct. 17 at 4:07 PM
$RLMD The wheels are finally falling off this one. They are out of money.
1 · Reply
OvercomingFears
OvercomingFears Oct. 16 at 4:05 AM
GIPR on a short squeeze mission, ✅ Low float+Fits the theme, this is how parabolic run starts, be early don't chase, ones this break $3 can quickly gap up. GIPR is the definition of overlooked value. ✅$13 true value ✅Massive tenants ✅Crypto treasury in the works Real estate is back and this one hasn’t moved — yet.✅ $NEUP $RLMD $SBFM $FEMY ..8
1 · Reply
mhaven2020
mhaven2020 Oct. 9 at 5:41 PM
$RLMD level 2 data
0 · Reply
mhaven2020
mhaven2020 Oct. 9 at 5:29 PM
$VRAR these are all of the alerts for the last month. Enjoy! $GXAI $NUAI $RLMD Check our website to sign up.
0 · Reply
teaman60
teaman60 Oct. 9 at 5:19 PM
$RLMD Wow it's quiet here. Stock has held nicely at $2 level
0 · Reply
teaman60
teaman60 Oct. 8 at 10:46 PM
$RLMD This is going nowhere for awhile. The management is lacking and the money to see their mission thru us not there. They have little choice but to sell to a larger partner
0 · Reply
RiskCPremium
RiskCPremium Oct. 7 at 3:03 PM
$RLMD Relmada needs a clean break from Sergio Traversa. Paolo, Marco, Inturrisi, Maurizio et al. in order to have a fresh start. Relmada needs fund to move forward with NDV-01 trial. Market/analysts/shareholders do not have any confidence in honesty & integrity of current leadership.
1 · Reply
teaman60
teaman60 Oct. 7 at 2:10 PM
$RLMD The big sales don't stop
0 · Reply
Latest News on RLMD
Relmada Issues Mid-Year CEO Letter to Shareholders

Sep 10, 2025, 7:15 AM EDT - 6 weeks ago

Relmada Issues Mid-Year CEO Letter to Shareholders


Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript

May 12, 2025, 10:02 PM EDT - 5 months ago

Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript


UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 27, 2025, 9:00 AM EDT - 6 months ago

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025


Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Apr 24, 2025, 8:00 AM EDT - 6 months ago

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data


Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 14, 2025, 7:30 AM EDT - 6 months ago

Relmada Therapeutics To Present NDV-01 Data at AUA2025


signaljumper
signaljumper Oct. 20 at 4:43 PM
$RLMD loading at this area
0 · Reply
VictorMason
VictorMason Oct. 20 at 4:05 PM
$RLMD Jan 23rd text to grandson: Im buying 20,000 RLMD at .36 $7200 in anticipation of something happening w the dissolution of assets planned. The Net Operating Loss of $640MM is worth at least $3/ share to a profitable pharma, the Relight phase 3 and develop the P-12 are valuable as is the $1 per share in cash
2 · Reply
RebelWithoutAPause777
RebelWithoutAPause777 Oct. 17 at 4:07 PM
$RLMD The wheels are finally falling off this one. They are out of money.
1 · Reply
OvercomingFears
OvercomingFears Oct. 16 at 4:05 AM
GIPR on a short squeeze mission, ✅ Low float+Fits the theme, this is how parabolic run starts, be early don't chase, ones this break $3 can quickly gap up. GIPR is the definition of overlooked value. ✅$13 true value ✅Massive tenants ✅Crypto treasury in the works Real estate is back and this one hasn’t moved — yet.✅ $NEUP $RLMD $SBFM $FEMY ..8
1 · Reply
mhaven2020
mhaven2020 Oct. 9 at 5:41 PM
$RLMD level 2 data
0 · Reply
mhaven2020
mhaven2020 Oct. 9 at 5:29 PM
$VRAR these are all of the alerts for the last month. Enjoy! $GXAI $NUAI $RLMD Check our website to sign up.
0 · Reply
teaman60
teaman60 Oct. 9 at 5:19 PM
$RLMD Wow it's quiet here. Stock has held nicely at $2 level
0 · Reply
teaman60
teaman60 Oct. 8 at 10:46 PM
$RLMD This is going nowhere for awhile. The management is lacking and the money to see their mission thru us not there. They have little choice but to sell to a larger partner
0 · Reply
RiskCPremium
RiskCPremium Oct. 7 at 3:03 PM
$RLMD Relmada needs a clean break from Sergio Traversa. Paolo, Marco, Inturrisi, Maurizio et al. in order to have a fresh start. Relmada needs fund to move forward with NDV-01 trial. Market/analysts/shareholders do not have any confidence in honesty & integrity of current leadership.
1 · Reply
teaman60
teaman60 Oct. 7 at 2:10 PM
$RLMD The big sales don't stop
0 · Reply
RiskCPremium
RiskCPremium Oct. 7 at 5:35 AM
$RLMD @thegodsmustbecrazy - Bottom line is Sergio Traversa, current MGNT, and BOD are albatrosses necklace around the neck of shareholders, NDV-01, and $RLMD. That's why stock is trading at $2.0 but TP is $1.0. None of the analysts who covered RLMD since 2019 no longer covering it. In Sept 2025, Sergio could not secure an invitation to attend investors' confs run by respectable Investment Bankers, even the ones who put their neck out for Sergio/RLMD till Dec 2024. According to SIDOTI, their niche clients are those who cannot obtain traditional brokerage/analyst coverage. Trying to convince me about potential of NDV-01 gel is like singing to the choir. I know RLMD is very active lately in X/twitter. I would not be surprised if there are some folks here in stocktwits.com singing for Sergio. If last 13 years is any indication, what is good for Sergio, Paolo, Marco, Ottavio, Inturrisi, and et al., is not good for RLMD. RLMD/NDV-01 has great potential w/o these scums.
2 · Reply
TheGodsMustBeCrazy
TheGodsMustBeCrazy Oct. 7 at 3:16 AM
$RLMD @RiskCPremium Bottom line, the phase 2 has shown incredible results, which is what you'd expect b\c everyone knows that gem\doce work really well and it's obvious that a sustained-release is going to work really well. So I think shepherding this asset to success is going to be very easy and even a monkey could do it. The brilliance in this story was when Sergio in-licensed the asset earlier this year. That was the coup. Hats off to Sergio, I say.
0 · Reply
TheGodsMustBeCrazy
TheGodsMustBeCrazy Oct. 7 at 3:08 AM
Hey @RiskCPremium, I feel your pain. I really do. I got burned by $RLMD's prior crashes too. But it's very common for a Phase III trial to fail. It happens. It's painful, but it happens. 🤷‍♀️ That said, personally, I think Sergio is a fine CEO for what we need. For two reasons: 1. NDV-01 is a layup in regards to: success of trials (it's obvious going to show great efficacy), FDA approval (FDA is obviously going to bend over backwards to approve this), and market uptake (I think it's going to launch incredibly fast\well; docs are clamoring for it). It's obviously going to be very successful and be worth $1-3B dollars, IMO. 2. Lastly, don't forget that <<SERGIO IS THE ONE>> who in-licensed NDV-01. And the terms of the deal were incredibly favorable: $3M UPFRONT, 3M SHARES, 3% ROYALTIES. I.e. he got it for us for a song. That's a huge feat that we are all now benefiting from. You have to give him huge credit for that, IMO.
0 · Reply
Elegant_Confusion
Elegant_Confusion Oct. 7 at 1:43 AM
$RLMD several insiders purchased RLMD in August and September, including CEO Sergio Traversa (CEO), who increased his holdings to 1,000,000 shares, noting his strong conviction in the company's undervalued status and its innovative pipeline. There were no insider sales in the same.
1 · Reply
TheGodsMustBeCrazy
TheGodsMustBeCrazy Oct. 6 at 7:32 PM
$RLMD Don't forget: until ~4 weeks ago, this stock was trading <$1/share, so major institutions could not even buy it. That all changed when RLMD recently readout their astounding data of 91% complete response rate. B\c of that, the stock soared above $1/share. Now many of these large biotech funds can finally BEGIN looking at RLMD. They are going to see that RLMD has an astounding 91% complete response rate, and will see that docs are craving for a sustained release form of gem\doce, and will realize that FDA approval is a lay-up, and these institutions are going to ascribe a sizeable value to RLMD of at least $500M ($11/share), if not multi-billion.
2 · Reply
TheGodsMustBeCrazy
TheGodsMustBeCrazy Oct. 6 at 7:24 PM
Even at $10/share, $RLMD would cheap, let alone at $1.98/share. The current market cap of $58M ($1.98/share) is a joke given how great their data are: 91% complete response rate is astounding (that's why stock has soared ~300% over past few weeks). I still expect institutions to load up soon and for this to become a biotech darling and for all of us to look back at 1.98/share as an incredible buying opportunity.
0 · Reply
TheGodsMustBeCrazy
TheGodsMustBeCrazy Oct. 6 at 7:18 PM
I expect $RLMD to be worth $2B in market cap, ie $54/share long term. Today's sale is a gift.
0 · Reply
teaman60
teaman60 Oct. 6 at 6:49 PM
$RLMD There is no bottom to this. The sells are huge and my guess it's insiders
0 · Reply
JasonBudd06
JasonBudd06 Oct. 6 at 6:06 PM
$RLMD everything will be just fine here
2 · Reply
teaman60
teaman60 Oct. 6 at 4:23 PM
$RLMD Now it's acting as I thought it would. The trend is not our friend
0 · Reply
TheGodsMustBeCrazy
TheGodsMustBeCrazy Oct. 6 at 4:49 AM
0 · Reply
TheGodsMustBeCrazy
TheGodsMustBeCrazy Oct. 5 at 5:39 AM
No, you have wrong information. $RLMD shut down the program you are referring to. RLMD is now all about their new asset, which is for bladder cancer. It's a very simple but amazing product; it's a sustained-release formulation of two chemotherapies: gem+doce. Their ongoing trial is in phase TWO, and shows 91% complete cure rate, which is astounding. There's a huge demand for a sustained-release formulation of gem+doce. Given the 91% complete response rate, RLMD is probably worth $2B, ie $54/share.
1 · Reply